FrancophonIA/ELRC3.0 huggingface dataset:
English: M06-802 was a randomised open-label study comparing the safety, tolerability and antiviral activity of oncedaily and twice daily dosing of lopinavir/ritonavir tablets in 599 subjects with detectable viral loads while receiving their current antiviral therapy.
Slovenian: M06-802 je bila randomizirana, odprta študija, ki je primerjala varnost, prenašanje in protivirusno delovanje tablet lopinavirja/ritonavirja enkrat in dvakrat na dan pri 599 preiskovancih z ugotovljivim virusnim bremenom med njihovim trenutnim protivirusnim zdravljenjem.
English: - Lopinavir/ritonavir is prescribed for use in combination with other antiviral medicines.
Slovenian: - Lopinavir/ritonavir se uporablja v kombinaciji z drugimi protivirusnimi zdravili.
English: Lopinavir/ritonavir plasma concentrations may decrease due to CYP3A4 induction by bosentan.
Slovenian: Koncentracija lopinavirja/ritonavirja v plazmi se lahko zmanjša zaradi indukcije CYP3A4 z bosentanom.
English: − People taking lopinavir/ritonavir may still develop infections or other illnesses associated with HIV disease and AIDS.
Slovenian: - Osebe, ki jemljejo lopinavir/ritonavir, lahko še vedno zbolijo za okužbami ali drugimi boleznimi, povezanimi z boleznijo HIV in AIDS-om.
English: The study did not contain a control arm of patients not receiving lopinavir/ritonavir.
Slovenian: Raziskava ni obsegala kontrolnega kraka bolnikov brez lopinavirja/ritonavirja.
English: Herbal preparations containing St John's wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of lopinavir and ritonavir (see section 4.5).
Slovenian: Zdravila rastlinskega izvora, ki vsebujejo šentjanževko (Hypericum perf oratum)) zaradi tveganja za zmanjšanje plazemske koncentracije in zmanjšanje kliničnih učinkov lopinavirja in ritonavirja (glejte poglavje 4.5).
English: It may be difficult to tell which side effects have been caused by lopinavir/ritonavir and which may occur due to other medicines you take at the same time or by the complications of the HIV infection.
Slovenian: Včasih je težko ločiti neželene učinke zaradi lopinavirja/ritonavirja od neželenih učinkov zaradi drugih sočasno uporabljenih zdravil ali od zapletov okužbe z virusom HIV.
English: Ombitasvir/paritaprevir/rito navir + dasabuvir
Slovenian: ombitasvir/paritapre vir/ritonavir + dasabuvir
English: Most tyrosine kinase inhibitors such as dasatinib and nilotinib, vincristine, vinblastine
Slovenian: večina zaviralcev tirozin kinaze, kot so dasatinib, nilotinib, vinkristin in vinblastin
English: − HIV-1 integrase inhibitor (e.g. raltegravir);
Slovenian: Inhibitorji integraze raltegravir raltegravir:
English: The in vitro antiviral activity of lopinavir against laboratory and clinical HIV strains was evaluated in acutely infected lymphoblastic cell lines and peripheral blood lymphocytes, respectively.
Slovenian: Protivirusno delov anje in v itro Protivirusno delovanje lopinavirja proti laboratorijskim in kliničnim sevom virusa HIV so in vitro ocenili pri akutno okuženih limfoblastnih celičnih linijah (laboratorijski sevi) in limfocitih periferne krvi (klinični sevi).
English: Thyroid stimulating hormone (TSH) should be monitored in patients treated with levothyroxine at least the first month after starting and/or ending lopinavir/ritonavir treatment.
Slovenian: Pri bolnikih, ki se zdravijo z levotiroksinom, je treba spremljati ščitnico stimulirajoči hormon (TSH) vsaj prvi mesec po začetku in/ali koncu zdravljenja z lopinavirjem/ritonavirjem.
English: What Lopinavir/Ritonavir Mylan is and what it is used for
Slovenian: Kaj je zdravilo Lopinavir/ritonavir Mylan in za kaj ga uporabljamo
English: In addition to the mutations described above, mutations V32I and I47A have been observed in rebound isolates with reduced lopinavir susceptibility from protease inhibitor experienced patients receiving lopinavir/ritonavir therapy, and mutations I47A and L76V have been observed in rebound isolates with reduced lopinavir susceptibility from patients receiving lopinavir/ritonavir therapy.
Slovenian: Poleg zgoraj opisanih mutacij so opažali mutaciji V32I in I47A pri izolatih s preobratom, to je z manjšo občutljivostjo za lopinavir pri bolnikih izkušenih z zaviralci proteaz, ki so dobivali lopinavir/ritonavir.
English: Vorapaxar
Slovenian: vorapaksar
English: Increased plasma concentrations of vardenafil (see sections 4.4 and 4.5)
Slovenian: Večja koncentracija vardenafila v plazmi (glejte poglavji 4.4 in 4.5.
English: Since increased concentrations of HMG-CoA reductase inhibitors may cause myopathy, including rhabdomyolysis, the combination of these agents with Lopinavir/Ritonavir Mylan is contraindicated (see section 4.3).
Slovenian: Ker lahko večja koncentracija zaviralcev HMG-CoA reduktaze povzroči miopatijo, vključno z rabdomiolizo, je uporaba teh zdravil hkrati z zdravilom Lopinavir/ritonavir Mylan kontraindicirana (glejte poglavje 4.3).
English: Monitor for ADRs related to ceritinib.
Slovenian: Spremljajte neželene učinke, ki so v povezavi s ceritinibom.
English: People taking lopinavir/ritonavir may still develop infections or other illnesses associated with HIV disease and AIDS.
Slovenian: Osebe, ki jemljejo lopinavir/ritonavir, lahko še vedno zbolijo za okužbami ali drugimi boleznimi, povezanimi z boleznijo HIV in aidsom.
English: Increased plasma concentrations of lurasidone which may increase the potential for serious and/or life threatening reactions (see section 4.5)
Slovenian: Večja koncentracija lurasidona v plazmi, ki lahko poveča možnost za resne in/ali življenje ogrožajoče reakcije (glejte poglavje 4.5).
English: For plastic containers, use within 120 days after first opening.
Slovenian: Za vsebnike: porabiti v 120 dneh po prvem odprtju.
English: MARKETING AUTHORISATION NUMBER EU/1/15/1067/004 - 120 Film-coated tablets EU/1/15/1067/006 - 120x1 Film-coated tablets EU/1/15/1067/005 - 360 Film-coated tablets
Slovenian: ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/15/1067/004 - 120 filmsko obloženih tablet EU/1/15/1067/006 - 120 x 1 filmsko obložena tableta EU/1/15/1067/005 - 360 filmsko obloženih tablet
English: The 230/57.5 mg/m2 twice daily regimen without nevirapine and the 300/75 mg/m2 twice daily regimen with nevirapine provided lopinavir plasma concentrations similar to those obtained in adult patients receiving the 400/100 mg twice daily regimen without nevirapine.
Slovenian: Dvakrat dnevno odmerjenje 230 mg/57,5 mg/m2 brez nevirapina in 300 mg/75 mg/m2 dvakrat na dan z nevirapinom je v plazmi zagotovilo koncentracijo lopinavirja, podobno tisti pri odraslih bolnikih, ki so dobivali zdravilo po shemi 400 mg/100 mg dvakrat na dan brez nevirapina.
English: Consequently, concomitant administration of Lopinavir/Ritonavir Mylan and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4).
Slovenian: Zato sočasna uporaba zdravila Lopinavir/ritonavir Mylan in teh glukokortikoidov ni priporočljiva, razen če možna korist zdravljenja odtehta tveganja sistemskih učinkov kortikosteroidov (glejte poglavje 4.4).
English: Through Week 48, genotypic resistance testing results were available from 75 patients in the QD group and 75 patients in the BID group who had incomplete virologic response.
Slovenian: V 48.tednu so bili na voljo rezultati testiranja genotipske odpornosti za 75 bolnikov v skupini, ki je prejemala zdravilo 1 x dnevno, in za 75 bolnikov v skupini, ki je prejemala zdravilo 2 x dnevno in ki je imela nepopolen virološki odgovor.
English: Bepridil, Systemic Lidocaine, Quinidine:
Slovenian: bepridil, sistemski lidokain in kinidin bepridil, sistemski lidokain in kinidin:
English: Increased plasma concentrations of ranolazine which may increase the potential for serious and/or life-threatening reactions (see section 4.5).
Slovenian: Večja koncentracija ranolazina v plazmi, ki lahko poveča možnost za resne in/ali življenje ogrožajoče reakcije (glejte poglavje 4.5).
English: B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).
Slovenian: Predpisovanje in izdaja zdravila je le na recept (glej Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
English: − If you notice you miss a dose within 6 hours of your normal dosing time, take your missed dose as soon as possible, and then continue with your normal dose at the regular time as prescribed by your doctor.
Slovenian: - Če opazite, da ste pozabili vzeti odmerek zdravila v 6 urah od predvidenega časa jemanja, vzemite izpuščeni odmerek čim prej in nato nadaljujte z odmerjanjem kot običajno, kakor vam je predpisal zdravnik.
English: − If you notice you miss a dose within 12 hours of your normal dosing time, take your missed dose as soon as possible, and then continue with your normal dose at the regular time as prescribed by your doctor.
Slovenian: - Če opazite, da ste pozabili vzeti odmerek zdravila v 12 urah od predvidenega časa jemanja, vzemite izpuščeni odmerek čim prej in nato nadaljujte z odmerjanjem kot običajno, kakor vam je predpisal zdravnik.
English: Therefore, if coadministration of delamanid with lopinavir/ritonavir is considered necessary, very frequent ECG monitoring throughout the full delamanid treatment period is recommended (see section 4.5 and refer to the delamanid SmPC).
Slovenian: Zato se v primeru, če se sočasno dajanje delamanida z lopinavirjem/ritonavirjem smatra za potrebno, skozi celotno obdobje zdravljenja z delamanidom priporoča zelo pogosto spremljanje EKG-ja (glejte poglavje 4.5 in povzetek glavnih značilnosti zdravila za delamanid).
English: MARKETING AUTHORISATION NUMBER EU/1/15/1067/001 - 60 Film-coated tablets EU/1/15/1067/002 - 60x1 Film-coated tablets
Slovenian: ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/15/1067/001 - 60 filmsko obloženih tablet EU/1/15/1067/002 - 60 x 1 filmsko obložena tableta
English: Lopinavir AUC over a 12 hour dosing interval averaged 113.2 ± 60.5 μg•h/ml.
Slovenian: AUC lopinavirja med 12-urnim odmernim intervalom je bila v povprečju 113,2  60,5 g•h/ml.
English: Astemizole, terfenadine
Slovenian: Antihistaminiki astemizol, terfenadin
English: Lopinavir/ritonavir is not a cure for HIV infection or AIDS.
Slovenian: Lopinavir/ritonavir ne ozdravi okužbe z virusom HIV ali aidsa.
English: Through Week 96, genotypic resistance testing results were available from 25 patients in the QD group and 26 patients in the BID group who had incomplete virologic response.
Slovenian: V 96.tednu so bili rezultati testiranja genotipske odpornosti na voljo za 25 bolnikov v skupini, ki je jemala zdravilo 1 x dnevno in 26 bolnikov v skupini, ki je jemala zdravila 2 x dnevno in ki je imela nepopolen virološki odgovor.
English: Lopinavir/ritonavir is contraindicated in patients with severe liver impairment (see section 4.3).
Slovenian: Lopinavir/ritonavir je kontraindiciran pri bolnikih s hudo okvaro jeter (glejte poglavje 4.3).
English: The following table contains dosing guidelines for lopinavir/ritonavir tablets based on BSA when used in combination with efavirenz or nevirapine in children.
Slovenian: Spodnja preglednica vsebuje smernice za odmerjanje tablet z lopinavirjem/ritonavirjem na osnovi telesne površine pri kombiniranem zdravljenju z efavirenzom ali nevirapinom pri otrocih.
English: Pancreatitis1, vomiting, gastrooesophageal reflux disease, gastroenteritis and colitis, abdominal pain (upper and lower), abdominal distension, dyspepsia, haemorrhoids, flatulence Uncommon Gastrointestinal haemorrhage including gastrointestinal ulcer, duodenitis, gastritis and rectal haemorrhage, stomatitis and oral ulcers, faecal incontinence, constipation, dry mouth
Slovenian: Bolezni prebavil zelo pogosti driska, navzea pogosti pankreatitis1, bruhanje, gastroezofagealna refluksna bolezen, gastroenteritis in kolitis, bolečine v zgornjem in spodnjem delu trebuha, napihnjenost trebuha, dispepsija, hemeroidi, flatulenca občasni gastrointestinalna hemoragija, vključno z razjedami v prebavilih, duodenitis, gastritis in rektalna hemoragija, stomatitis in razjede v ustih, fekalna inkontinenca, zaprtje, suha usta
English: Lopinavir/ritonavir tablets have also shown less pharmacokinetic variability under all meal conditions compared to lopinavir/ritonavir soft capsules.
Slovenian: Prav tako je bila farmakokinetična variabilnost med uporabo tablet lopinavirja/ritonavirja ne glede na vrsto obroka hrane manjša kot med uporabo mehkih kapsul lopinavirja/ritonavirja.
English: Co-administration of ibrutinib and Lopinavir/Ritonavir Mylan may increase ibrutinib exposure which may increase the risk of toxicity including risk of tumor lysis syndrome.
Slovenian: Sočasna uporaba ibrutiniba in zdravila Lopinavir/ritonavir Mylan lahko poveča izpostavljenost ibrutinibu, kar lahko poveča tveganje za toksičnost, vključno s tveganjem za pojav sindroma tumorske lize.
English: If the co-administration of Lopinavir/Ritonavir Mylan with bupropion is judged unavoidable, this should be done under close clinical monitoring for bupropion efficacy, without exceeding the recommended dosage, despite the observed induction.
Slovenian: Če se sočasni uporabi zdravila Lopinavir/ritonavir Mylan in bupropiona ni mogoče izogniti, je treba med hkratno uporabo teh zdravil natančno klinično spremljati učinkovitost bupropiona; priporočenega odmerka se kljub opaženi indukciji ne sme preseči.
English: 200/50 mg
Slovenian: 200 mg/50 mg
English: 30 Film-coated tablets
Slovenian: 30 filmsko obloženih tablet
English: The absolute bioavailability of lopinavir co-formulated with ritonavir in humans has not been established.
Slovenian: Absolutna biološka uporabnost lopinavirja, v kombinaciji z ritonavirjem, pri ljudeh ni ugotovljena.
English: BSA (m2) = √ (Height (cm) X Weight (kg) / 3600)
Slovenian: * Telesno površino lahko izračunamo po enačbi telesna površina (m2) = √ (višina (cm) X telesna masa (kg) / 3600)
English: Suomi/Finland Mylan Finland OY Puh/Tel: +358 20 720 9555
Slovenian: Suomi/Finland Mylan Finland OY Puh/Tel: +358 20 720 9555 (Sverige/Ruotsi)
English: Increased risk of alanine transaminase (ALT) elevations (see section 4.5).
Slovenian: Povečano tveganje za povišanje alanin aminotransferaze (ALT) (glejte poglavje 4.5).
English: Lopinavir/Ritonavir Mylan must not be co-administered with oral midazolam (see section 4.3), whereas caution should be used with coadministration of Lopinavir/Ritonavir Mylan and parenteral midazolam.
Slovenian: Zdravila Lopinavir/ritonavir Mylan se ne sme uporabljati sočasno s peroralnim midazolamom (glejte poglavje 4.3), v primeru sočasne uporabe zdravila Lopinavir/ritonavir Mylan in parenteralnega midazolama pa je potrebna previdnost.
English: Phosphodiesterase (PDE5) inhibitors Avanafil (ritonavir 600 mg BID)
Slovenian: Zaviralci f osf odiesteraze (PDE5) avanafil (ritonavir 600 mg dvakrat na dan)
English: The Lopinavir/Ritonavir Mylan dose should be titrated upward only after rifampicin has been initiated (see section 4.4).
Slovenian: Odmerek zdravila Lopinavir/ritonavir Mylan je treba povečati šele po uvedbi rifampicina (glejte poglavje 4.4).
English: AUC: ↑ 2-fold
Slovenian: AUC: ↑ 2-krat
English: Thyroid-stimulating hormone (TSH) should be monitored in patients treated with levothyroxine at least the first month after starting and/or ending ritonavir treatment.
Slovenian: Pri bolnikih, ki se zdravijo z levotiroksinom, je treba vsaj prvi mesec po začetku in/ali koncu zdravljenja z ritonavirjem spremljati tirotropin (TSH).
English: Outcomes at Week 48: Study M98-940 Antiretroviral Naïve (N=44) Antiretroviral Experienced (N=56)
Slovenian: Rezultati v 48.tednu: Študija M98-940 Bolnik i, k i predhodno niso bili zdravljeni s protiretrovirusnimi zdravili (N=44)
English: Concomitant administration of Lopinavir/Ritonavir Mylan with colchicine in patients with renal and/or hepatic impairment is contraindicated due to a potential increase of colchicine-related serious and/or life-threatening reactions such as neuromuscular toxicity (including rhabdomyolysis) (see sections 4.3 and 4.4).
Slovenian: Sočasna uporaba zdravila Lopinavir/ritonavir Mylan s kolhicinom je kontraindicirana pri bolnikih z okvaro ledvic in/ali jeter, ker obstaja možnost povečanja resnih in/ali življenjsko ogrožajočih reakcij, povezanih s kolhicinom kot je živčno-mišična toksičnost (vključno z rabdomiolizo) (glejte poglavji 4.3 in 4.4).
English: Cushing's syndrome has been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolised via the P450 3A pathway e.g. budesonide (see section 4.4 and 4.5).
Slovenian: Pri bolnikih, ki so prejemali ritonavir in inhalacijsko ali intranazalno uporabljen flutikazon propionat, so poročali o Cushingovem sindromu; ta se lahko pojavi tudi pri uporabi drugihkortikosteroidov, ki se presnavljajo preko poti P450 3A, npr. budenozid (glejte poglavji 4.4 in 4.5).
English: Very common: may affect more than 1 in 10 people.
Slovenian: Zelo pogosti: pojavijo se lahko pri več kot 1 od 10 bolnikov - driska; - navzea; - okužbe zgornjih dihal.
English: The two regimens resulted in exposures on Day 3 which were approximately 1.5 and 3-fold higher than those observed with recommended oncedaily or twicedaily LPV/r doses at steady state.
Slovenian: Med tema režimoma uporabe je bila izpostavljenost 3. dan 1,5- oz. 3-krat večja, kot je ugotovljena med uporabo priporočenih odmerkov lopinavirja/ritonavirja enkrat oz. dvakrat na dan v stanju dinamičnega ravnovesja.
English: HIV CCR5 - antagonist Maraviroc
Slovenian: Zaviralci HIV CCR5
English: Increased plasma concentrations of paritaprevir; thereby, increasing the risk of alanine transaminase (ALT) elevations (see section 4.5).
Slovenian: Povečana koncentracija paritaprevirja v plazmi; zato je povečano tveganje za povišanje alanin aminotransferaze (ALT) (glejte poglavje 4.5).
English: Pregnancy and postpartum
Slovenian: Nosečnost in po porodu
English: NAME OF THE MARKETING AUTHORISATION HOLDER Mylan SAS
Slovenian: IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Mylan S.A.S.
English: Concomitant administration with colchicine is contraindicated in patients with renal and/or hepatic impairment (see sections 4.3 and 4.5).
Slovenian: Sočasna uporabi kolhicina je kontraindicirana pri bolnikih z okvaro ledvic in/ali jeter (glejte poglavji 4.3 in 4.5).
English: Colchicine:
Slovenian: kolhicin::
English: Rivaroxaban:
Slovenian: rivaroksaban:
English: Nucleoside/Nucleotide reverse transcriptase inhibitors (NRTIs) Stavudine, Lamivudine
Slovenian: Nukleozidni in nukleotidni zaviralci reverzne transkriptaze (NRTI) stavudin, lamivudin lopinavir: ↔
English: A more pronounced effect on bedaquiline plasma exposures may be observed during prolonged co-administration with lopinavir/ritonavir.
Slovenian: Bolj izrazit učinek na koncentracijo bedakilina v plazmi se lahko opazi med podaljšano sočasno uporabo z lopinavirjem/ritonavirjem.
English: Cpredose μg /mL
Slovenian: Cmax Cpred odmerkom μg /ml
English: Acid reducing agents
Slovenian: Zdravila za zniževanje lipidov
English: Rilpivirine:
Slovenian: rilpivirin:
English: Since lopinavir/ritonavir is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the active substance.
Slovenian: Ker je lopinavir/ritonavir v veliki meri vezan na beljakovine, ni verjetno, da bi dializa pomembno odstranila zdravilno učinkovino.
English: The lopinavir mean steady-state AUC, Cmax, and Cmin were 72.6 ± 31.1 μg•h/ml, 8.2 ± 2.9 μg/ml and 3.4 ± 2.1 μg/ml, respectively after lopinavir/ritonavir oral solution 230/57.5 mg/m2 twice daily without nevirapine (n=12), and were 85.8 ± 36.9 μg•h/ml, 10.0 ± 3.3 μg/ml and 3.6 ± 3.5 μg/ml, respectively after 300/75 mg/m2 twice daily with nevirapine (n=12).
Slovenian: Povprečne AUC, Cmax in Cmin v stanju dinamičnega ravnovesja lopinavirja so bile v skupini, ki je prejemala 230/57,5 mg/m2, dvakrat na dan brez nevirapina (n = 12); 72,6 ± 31,1 μg•h/ml, 8,2 ± 2,9 μg/ml in 3,4 ± 2,1 μg/ml; v skupini, ki je prejemala 300 mg/75 mg/m2, dvakrat na dan z nevirapinom (n = 12) pa; 85,8 ± 36,9 μg•h/ml, 10,0 ± 3,3 μg/ml in 3,6 ± 3,5 μg/ml.
English: - Multipack containing 360 (3 bottles of 120) film-coated tablets.
Slovenian: - Skupno pakiranje s 360 (3 vsebniki s 120) filmsko obloženimi tabletami.
English: Trazodone: AUC: ↑ 2.4-fold
Slovenian: trazodon: AUC: ↑ 2,4-krat
English: In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection.
Slovenian: Po začetku jemanja zdravil za zdravljenje vaše okužbe z virusom HIV se lahko poleg oportunističnih infekcij pojavijo tudi avtoimunske bolezni (stanje, ki se pojavi, ko imunski sistem napade zdravo tkivo).
English: Antiviral activity of lopinavir/ritonavir in patients failing protease inhibitor therapy The clinical relevance of reduced in vitro susceptibility to lopinavir has been examined by assessing the virologic response to lopinavir/ritonavir therapy, with respect to baseline viral genotype and phenotype, in 56 patients previous failing therapy with multiple protease inhibitors.
Slovenian: Klinični pomen zmanjšane občutljivosti za lopinavir in vitro so raziskali z oceno virološkega odziva na zdravljenje z lopinavirjem/ritonavirjem (upoštevaje izhodiščni virusni genotip in fenotip) pri 56 bolnikih s predhodno neuspešnim zdravljenjem z več zaviralci proteaz.
English: Co-administration of rivaroxaban and Lopinavir/Ritonavir Mylan may increase rivaroxaban exposure which may increase the risk of bleeding.
Slovenian: Sočasna uporaba rivaroksabana in zdravila Lopinavir/ritonavir Mylan lahko poveča izpostavljenost rivaroksabanu, kar lahko poveča tveganje za krvavitev.
English: Opioids Buprenorphine, 16 mg QD Buprenorphine: ↔
Slovenian: Opioidi buprenorfin, 16 mg enkrat na dan buprenorfin: ↔
English: The concomitant administration with lurasidone is contraindicated (see section 4.3).
Slovenian: Sočasna uporaba z lurasidonom je kontraindicirana (glejte poglavje 4.3).
English: HDPE bottle: After first opening, use within 120 days.
Slovenian: HDPE vsebnik: Po prvem odprtju porabiti v 120 dneh.
English: Tell your doctor if you experience nausea, vomiting or abdominal pain as these may be suggestive of pancreatitis (inflammation of the pancreas).
Slovenian: zdravniku povejte, če vam je slabo, bruhate ali vas boli trebuh, ker bi to lahko kazalo na pankreatitis (vnetje trebušne slinavke).
English: Increased risk of side-effects (respiratory depression, sedation) due to higher plasma concentrations because of CYP3A4 inhibition by lopinavir/ritonavir.
Slovenian: Povečano tveganje za neželene učinke (dihalna stiska, sedacija) zaradi višjih plazemskih koncentracij, ki jih povzroči lopinavir/ritonavir z inhibicijo CYP3A4.
English: In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
Slovenian: Pri z virusom HIV okuženih bolnikih s hudo imunsko pomanjkljivostjo lahko ob uvedbi kombiniranega protiretrovirusnega zdravljenja (CART - ''combination antiretroviral therapy'') nastane vnetna reakcija na asimptomatične ali rezidualne oportunistične okužbe.
English: In the absence of human serum, the mean IC50 of lopinavir was 6.5 nM against several HIV-1 clinical isolates.
Slovenian: V odsotnosti humanega seruma je bila povprečna IC50 lopinavirja proti več kliničnim izolatom HIV-1 6,5 nM.
English: Other medicines and Lopinavir/Ritonavir Mylan
Slovenian: Druga zdravila in zdravilo Lopinavir/ritonavir Mylan
English: Cmax: ↑ 5-fold
Slovenian: Cmax: ↑ 5-krat
English: Concomitant administration of Lopinavir/Ritonavir Mylan and quetiapine is contraindicated as it may increase quetiapine-related toxicity.
Slovenian: Sočasna uporaba zdravila Lopinavir/ritonavir Mylan in kvetiapina je kontraindicirana, ker lahko poveča toksičnost, povezano s kvetiapinom.